Deals & Cases

Schellenberg Wittmer advised SPRIM Global Investments in a capital commitment of USD 4.5 million


Schellenberg Wittmer acted as Swiss counsel to SPRIM Global Investments (SGI), a leading health sciences venture capital firm, in its capital commitment of USD 4.5 million in favor of Spexis AG, a clinical-stage and biopharmaceutical company listed on the SIX Swiss Exchange, to enable initiation of ColiFin® Phase 3 study.

The commitment was structured as a mix of secured debt and subordinated debt mandatorily converting into equity.

The Schellenberg Wittmer team consisted of Tarek Houdrouge (overall lead), Jérémie Tenot (Banking & Finance) and Alexander Zundel (Corporate/M&A).


Stay up to date!

*Required fields

Newsletters & Newsflashes

Monthly selected key topics from our practice areas, sectors and industries, plus newsflashes on recent developments.


Monthly email with the latest updates and summaries of the Swiss Federal Supreme Court's case law in arbitration matters.
Regular insights into Swiss and international trends and legal developments in the construction industry.
Regular insights and updates on key developments in the rapidly changing landscape of Environmental, Social and Corporate Governance disputes.
Concise analysis of key trends in the fast-moving world of corporate governance for board members of Swiss companies.
A regular look from a unique M&A perspective at legal changes, economic developments and societal trends in Switzerland.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.